Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Oncocyte Corporation (OCX) delivers innovative molecular diagnostics through non-invasive liquid biopsy tests and transplant monitoring solutions. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in early cancer detection and organ rejection diagnostics.
Access official press releases, clinical trial milestones, and partnership announcements in one centralized location. Track developments across key areas including diagnostic product launches, regulatory progress, and strategic collaborations that shape Oncocyte’s role in precision medicine.
Our curated news collection features updates on proprietary technologies like VitaGraft Kidney and DetermaIO, alongside financial performance reports and research breakthroughs. Stay informed about how OCX’s digital PCR-based assays address critical needs in oncology and transplant care.
Bookmark this page for streamlined access to verified Oncocyte Corporation updates. Check regularly for new developments impacting diagnostic innovation and clinical decision-making tools.
Oncocyte (Nasdaq: OCX) has successfully launched GraftAssure™, a research-use-only assay detecting graft organ damage in blood. The assay debuted in July 2024 at major transplant centers in the U.S. and Asia. The company reported Q2 2024 revenue of $104,000, a $4.5 million loss from continuing operations, and an $11 million cash balance. The GraftAssure launch is part of a strategy to capture market share in a $1 billion market, aligning with Bio-Rad's global infrastructure. Positive momentum is reported from partnerships and industry relationships. Oncocyte aims to establish over 20 transplant centers running GraftAssure by the end of 2025, targeting significant future revenue. The company is also preparing for FDA IVD clearance in late 2025. Andrea James has been appointed CFO. Additional details are in the company's updated investor deck.
Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, has announced its participation in two investor conferences this August. CEO Josh Riggs and CFO Andrea James will represent the company at:
1. The 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference on August 12-13, 2024, where they plan to host meetings with investors.
2. The Sidoti Micro-Cap Virtual Conference on August 14-15, 2024. Oncocyte is scheduled to present on Wednesday, August 14, from 1:00 PM to 1:30 PM ET in Track 3, and will also participate in one-on-one meetings.
Investors interested in scheduling meetings with Oncocyte's management team can contact their Needham or Sidoti representative or reach out to the company's IR contact directly.
Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, has announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close. The company will host a conference call and webcast on the same day at 5:00 p.m. Eastern Time to discuss its financial results and highlights.
Interested parties can access the live call via telephone by dialing toll-free 800-715-9871 for domestic callers. The live webcast can be accessed through the 'Events & Presentations' section of Oncocyte's website. A replay of the webcast will be available on the company's website shortly after the call concludes.
Oncocyte (Nasdaq: OCX), a precision diagnostics company, has appointed Andrea James as Chief Financial Officer effective June 17, 2024. Andrea James brings extensive experience in financial strategy, investor relations, and capital raising from her previous roles at Axon Enterprise and Tesla. Her appointment comes as Oncocyte approaches significant commercialization milestones and aims to expand its diagnostic tool usage in the transplant community and oncology space through partnerships. Ms. James holds a BS in Computer Information Systems and an MS in Journalism. She will be pivotal in guiding Oncocyte through transformative years ahead.
On May 30, 2024, Oncocyte announced that favorable results for its VitaGraft Kidney test were published in the New England Journal of Medicine. Data from a phase 2 study indicated that the test could monitor graft injury and identify responses to the investigational drug felzartamab. Results showed significant reductions in donor-derived cell-free DNA (dd-cfDNA) levels at weeks 12 and 24. This advancement suggests potential new uses for VitaGraft Kidney in monitoring therapeutic efficacy and recurrence of antibody-mediated rejection (AMR) in kidney transplant patients. Up to 20.2% of kidney transplant patients develop AMR within 10 years, often leading to graft failure. Oncocyte’s CEO, Josh Riggs, emphasized the potential for VitaGraft to improve care and outcomes for high-risk patients.
Oncocyte (Nasdaq: OCX) reported Q1 2024 financial results, highlighting key developments. The company formed a global commercialization partnership with Bio-Rad Labs, raised $15.8M from equity private placement, and reduced cash burn to $3.9M. However, net revenue fell by 41% YOY to $176K. Research and development expenses rose by 2% to $2.2M, while general and administrative expenses decreased by 22% to $2.7M. The loss from operations was $9.3M, compared to a $5.9M income in Q1 2023, mainly due to a $3.3M loss from the change in fair value of contingent consideration. Oncocyte is set to ship its GraftAssure transplant monitoring test kits globally in 2Q 2024 and is advancing other diagnostic tests.
Oncocyte (Nasdaq: OCX) will release its first quarter 2024 financial results on May 15, 2024, after the U.S. market closes. A conference call and webcast will be held on the same day at 4:30 p.m. ET to discuss the results.
FAQ
What is the current stock price of Oncocyte Corporation (OCX)?
What is the market cap of Oncocyte Corporation (OCX)?
